Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.

Hsu CK, Hsu CC, Lee JY, Kuo YM, Pai MC.

J Am Acad Dermatol. 2013 Feb;68(2):e46-8. doi: 10.1016/j.jaad.2012.07.012. No abstract available.

PMID:
23317986
[PubMed - indexed for MEDLINE]
2.

[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].

Trechot P, Schmutz JL.

Ann Dermatol Venereol. 2013 Oct;140(10):669-70. doi: 10.1016/j.annder.2013.06.003. Epub 2013 Jul 29. French. No abstract available.

PMID:
24090904
[PubMed - indexed for MEDLINE]
3.

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

Cummings J.

Biol Psychiatry. 2010 Nov 15;68(10):876-8. doi: 10.1016/j.biopsych.2010.09.020. No abstract available.

PMID:
21035622
[PubMed - indexed for MEDLINE]
4.

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ.

Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.

PMID:
18695053
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

Schor NF.

Ann Neurol. 2011 Feb;69(2):237-9. doi: 10.1002/ana.22365.

PMID:
21387368
[PubMed - indexed for MEDLINE]
6.

[Gamma-secretase inhibitors and modulators].

Iwai A.

Nihon Rinsho. 2011 Dec;69 Suppl 10(Pt 2):83-7. Review. Japanese. No abstract available.

PMID:
22755160
[PubMed - indexed for MEDLINE]
7.

ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

Hopkins CR.

ACS Chem Neurosci. 2010 Aug 18;1(8):533-4. doi: 10.1021/cn1000606.

PMID:
22778845
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

Imbimbo BP, Peretto I.

Curr Opin Investig Drugs. 2009 Jul;10(7):721-30.

PMID:
19579178
[PubMed - indexed for MEDLINE]
9.

Drugs: a tangled web of targets.

Gravitz L.

Nature. 2011 Jul 13;475(7355):S9-11. doi: 10.1038/475S9a. No abstract available.

PMID:
21760583
[PubMed - indexed for MEDLINE]
10.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC.

Neurology. 2006 Feb 28;66(4):602-4.

PMID:
16505324
[PubMed - indexed for MEDLINE]
11.

Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

Hyde LA, McHugh NA, Chen J, Zhang Q, Manfra D, Nomeir AA, Josien H, Bara T, Clader JW, Zhang L, Parker EM, Higgins GA.

J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43. Epub 2006 Aug 31.

PMID:
16946102
[PubMed - indexed for MEDLINE]
Free Article
12.

Semagacestat for treatment of Alzheimer's disease.

Pomara N.

N Engl J Med. 2013 Oct 24;369(17):1661. doi: 10.1056/NEJMc1310845#SA2. No abstract available.

PMID:
24152269
[PubMed - indexed for MEDLINE]
13.

Semagacestat for treatment of Alzheimer's disease.

Gupta VB, Gupta VK, Martins R.

N Engl J Med. 2013 Oct 24;369(17):1660-1. doi: 10.1056/NEJMc1310845#SA1. No abstract available.

PMID:
24152268
[PubMed - indexed for MEDLINE]
14.

Semagacestat for treatment of Alzheimer's disease.

Doody RS, Aisen PS, Iwatsubo T.

N Engl J Med. 2013 Oct 24;369(17):1661. doi: 10.1056/NEJMc1310845. No abstract available.

PMID:
24152267
[PubMed - indexed for MEDLINE]
Free Article
15.

Molecule of the month. Semagacestat.

[No authors listed]

Drug News Perspect. 2008 Sep;21(7):390. No abstract available.

PMID:
19259551
[PubMed - indexed for MEDLINE]
16.

Genetics. Gamma-secretase and human disease.

Kelleher RJ 3rd, Shen J.

Science. 2010 Nov 19;330(6007):1055-6. doi: 10.1126/science.1198668. No abstract available.

PMID:
21097925
[PubMed - indexed for MEDLINE]
17.

[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].

Shitaka Y, Mitani Y, Nagakura A, Miyake A, Matsuoka N.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):15-20. Review. Japanese. No abstract available.

PMID:
20628208
[PubMed - indexed for MEDLINE]
18.

Semagacestat's fall: where next for AD therapies?

Blennow K, Zetterberg H, Haass C, Finucane T.

Nat Med. 2013 Oct;19(10):1214-5. doi: 10.1038/nm.3365. No abstract available.

PMID:
24100981
[PubMed - indexed for MEDLINE]
19.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. Review.

PMID:
22087836
[PubMed - indexed for MEDLINE]
20.

New pathway links γ-secretase to inflammation and memory while sparing notch.

Gandy S, Wustman B.

Ann Neurol. 2011 Jan;69(1):5-7. doi: 10.1002/ana.22310. No abstract available.

PMID:
21280069
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk